Sweden's XVIVO Q3 revenue beat expectations on thoracic sales

Overview

• Sweden medical technology firm's Q3 sales rose 34% yr/yr, beating analyst expectations

• Adjusted EPS for Q3 rose to SEK 1.42, no analyst estimate provided

• Company received CE certificate for Heart Assist Transport System and advanced clinical trials

Outlook

• Company did not provide specific financial guidance for the current or coming periods in the press release

Result Drivers

• THORACIC SALES - Co said thoracic sales increased by 51% in local currencies, helping drive overall growth

• ABDOMINAL SALES - Co reported abdominal sales rose 12% in local currencies

• SERVICE SALES DECLINE - Co said services sales decreased by 28% in local currencies, partially offsetting growth in other segments

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Xvivo Perfusion AB is SEK330.00, about 45.6% above its October 21 closing price of SEK226.60

• The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 52 three months ago

Reuters Recommended Reads

• Oct 22 - Sweden's Arjo Q3 revenue beats estimates, gross margin expands

• Oct 22 - Sweden's Sedana Medical Q3 sales rise as growth returns

• Oct 21 - Medical gear maker Getinge beats Q3 profit estimates on pricing, product mix

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)